Sun Yat-sen University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

976

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

98 drugs in development

Approved7

Phase 324

Phase 272

Phase 16

Preclinical14

By Therapeutic Area

top 6

Oncology

9174%

Cardiovascular

43%

Metabolic & Endocrine

22%

Infectious Disease

22%

Musculoskeletal

22%

Nephrology

22%

R&D Momentum

100/100

Pipeline Velocity

83/100

Trial Completion Rate

75/100

Pipeline Concentration

56/100

Pipeline Freshness

42/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 8, 2026

Active, not recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Jul 3, 2026

Recruiting

Hepatic Arterial Infusion or Intravenous Infusion of Adebrelimab, Combined With Bevacizumab and Hepatic Arterial Infusion of FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma: a Multicenter, Open Label, Randomized Phase II Trial

Jul 2, 2026

Recruiting

A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Earlier

Jun 30, 2026TrialManagement Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC: A Multi-center Prospective Study in China

Jun 30, 2026TrialToripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial

Jun 27, 2026TrialThe Effects of Nudging Intervention in Promoting Adherence to Anticoagulation Among Patients With Atrial Fibrillation: a Randomized Controlled Trail

Jun 26, 2026TrialA Multicenter, Single-Arm, Phase II Trial of Neoadjuvant Docetaxel and Cisplatin Combined With Dual Immunotherapy for Locally Advanced Sinonasal Carcinoma (PANDA Study)

Jun 25, 2026TrialCadonilimab (Bispecific Anti-PD-1/CTLA-4 Antibody) for PD-1/PD-L1 Blockade-refractory, Microsatellite Instability-high (MSI-H) or Mismatch Repair-deficient (dMMR), Advanced Colorectal Cancer: a Single Group, Multicenter, Phase 2 Trial

3 more events

Jun 24, 2026TrialEfficacy and Safety of Allogeneic Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Patients With Acute-on-chronic Liver Failure

Jun 24, 2026TrialCamrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, Phase Ib/II Clinical Study

Jun 24, 2026TrialIndividualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma: A Non-Inferiority, Multicenter, Randomized Phase 3 Trial

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(4 drugs)

Gastroenterology(2 drugs)

—

Gastroenterology(2 drugs)

Hematology(2 drugs)

—

Hematology(2 drugs)

Immunology(1 drug)

—

Immunology(1 drug)

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(2 drugs)

—

Metabolic & Endocrine(2 drugs)

Musculoskeletal(2 drugs)

—

Musculoskeletal(2 drugs)

Nephrology(2 drugs)

—

Nephrology(2 drugs)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(91 drugs)

Ophthalmology(2 drugs)

—

Ophthalmology(2 drugs)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Rare Disease(1 drug)

—

Rare Disease(1 drug)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(9 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)